39 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 39 separate news trends connected to Eli Lilly, spanning June 23, 2026 through October 2, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 337 article observations and 312 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
Foghorn Therapeutics slashes 40% of staff after Lilly aborts a cancer partnership, sending its shares sharply lower.
Novo Nordisk's shares dropped as Eli Lilly gains ground in GLP-1s
Viking Therapeutics stock surges 30% on positive obesity drug trial results.
700,000 seniors start GLP-1 treatments under Medicare, with 70% on Eli Lilly drugs
Eli Lilly stakes $6.5 billion on a Houston plant as its GLP‑1 drugs dominate Medicare prescriptions
Novo Nordisk has signed an up to $1.4 billion licensing deal with Danish biotech Orbis Medicines to develop oral macrocycle drugs for cardiometabolic diseases.
Investors in Novo Nordisk are on edge as the pharmaceutical giant faces increasing competition in the GLP-1 market.
Eli Lilly's $2.88 billion bid for Merida Biosciences marks its 13th 2026 acquisition, swelling Massachusetts biotech staffing.
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
Eli Lilly's acquisition of Merida Biosciences for up to $2.875 billion is making waves in the biotech industry.
Some companies are reconsidering their insurance policies for GLP-1 weight loss drugs, affecting employee benefits.
The FDA's approval of Lilly's Mounjaro for cardiovascular risk reduction is a major win for the company and a potential game-changer for diabetes patients.
Millions of Medicare patients with qualifying diagnoses are excluded from a new GLP-1 discount program.
The FDA has granted clearance for the first blood-based biomarker test for Alzheimer's disease, developed through a partnership between Roche and Eli Lilly.
Eli Lilly's new weight-loss pill Foundayo is now available in the U.K., marking a significant milestone in the pharmaceutical industry.
Researchers are finding new benefits of GLP-1 medications, shifting the conversation beyond weight loss.
Eli Lilly is suing six companies to stop illegal sales of its unapproved weight loss drug, retatrutide.
Eli Lilly is suing companies over the illegal sales of its experimental weight-loss drug, retatrutide.
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
CVS Health is expanding access to weight-loss treatments through a new Eli Lilly partnership, resulting in an updated financial outlook for the company.
CVS Health's stock is falling despite a strong earnings report, due to a cautious outlook for 2027.
Eli Lilly's stock surges as demand for its weight-loss drugs continues to drive revenue growth.
Divergent earnings reports this week reveal a surge in pharmaceutical demand alongside cooling momentum in the digital advertising sector.
Novo Nordisk's stock price drops despite beating earnings forecasts, as investors react to revised guidance.
Investors brace for a $225 billion swing in SpaceX's value as the company's first earnings report approaches.
Eli Lilly is expanding access to its experimental obesity drug, Retatrutide, ahead of approval.
Eli Lilly has shifted the FDA application timeline for its next-generation obesity drug, retatrutide, to the first quarter of 2027.
Eli Lilly's retatrutide shows promising results in weight loss trials, driving stock gains and regulatory anticipation
Eli Lilly is advancing toward a 2027 regulatory filing for retatrutide following successful Phase 3 obesity trial results.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the rival company used false and misleading advertising regarding weight-loss drug efficacy.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the use of misleading and deceptive advertising for GLP-1 weight-loss drugs.
Peptides are gaining broad attention across regulatory, skincare, and investment sectors following recent FDA scrutiny and market analysis.
Eli Lilly is reportedly nearing a deal to acquire psychedelic drugmaker AtaiBeckley, triggering a sharp surge in the company's stock price.
Eli Lilly's market value surges as Kailera's weight-loss pill faces market setbacks despite successful clinical efficacy in China.
The FDA is launching a pilot program to accelerate the review process for new pharmaceutical manufacturing facilities, starting with Eli Lilly and Regeneron.
Eli Lilly shares have hit a new all-time high following European regulatory progress and expanded access to GLP-1 treatments.
Eli Lilly's Jaypirca has received a positive CHMP recommendation for the treatment of chronic lymphocytic leukemia (CLL) in the European Union.
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.
Speculation swirls around a 79-year-old patient who received an experimental weight loss drug, with former President Trump as the suspected recipient.